Ever since Amarin's (NASDAQ:AMRN) new drug Vascepa, which lowers triglyceride levels, was approved in July, the biotech space has been rife with talk of a buyout. It has been previously reported that AstraZeneca (NYSE:AZN) might be considering this purchase, but now an unexpected new company has stepped into the story.

In this video, Motley Fool health care analyst Max Macaluso discusses Teva Pharmaceutical's (NYSE:TEVA) possible interest in Amarin and whether this drugmaker would actually be a better match than AstraZeneca.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.